A clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and other conditions affecting the central nervous system. The firm gained market attention after securing and later withdrawing U.S. approval for its ...
1 member of Congress has disclosed 1 trade in Amylyx Pharmaceuticals, Inc. (AMLX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-10-12 | Christopher L. Jacobs | buy | $1K – $15K |